Glenview Trust Co Sells 23,367 Shares of Novo Nordisk A/S $NVO

Glenview Trust Co reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 77.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 6,961 shares of the company’s stock after selling 23,367 shares during the quarter. Glenview Trust Co’s holdings in Novo Nordisk A/S were worth $354,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of NVO. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the 3rd quarter worth $25,000. WealthCollab LLC raised its holdings in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $28,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Finally, Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Down 1.6%

Shares of NVO stock opened at $44.26 on Wednesday. The stock has a market cap of $197.62 billion, a P/E ratio of 10.39, a PEG ratio of 4.01 and a beta of 0.77. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company’s fifty day simple moving average is $40.55 and its two-hundred day simple moving average is $46.39.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current fiscal year.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s Wegovy pill has received CHMP backing in the EU, moving it closer to approval and potentially making it the first oral GLP-1 treatment for obesity in Europe. That could expand the addressable market and support future sales growth. CHMP Backs EU Approval of Novo Nordisk’s Wegovy Pill for Obesity
• Positive Sentiment: The company also announced a share repurchase program, which can support the stock by signaling management confidence and reducing the share count over time. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: New POSEIDON study findings highlighted a high level of cardiovascular inflammation in patients with heart disease, reinforcing an unmet need that Novo Nordisk’s cardiometabolic portfolio could help address. Novo Nordisk POSEIDON Data Highlights Residual Inflammatory Risk And New Opportunity
• Positive Sentiment: Another report said Novo Nordisk nears EU approval for oral Wegovy, adding to optimism around the company’s GLP-1 pipeline and future revenue potential. Novo Nordisk Nears EU Nod For Oral Wegovy And Investor Opportunity
• Neutral Sentiment: Several commentary pieces kept Novo Nordisk in the spotlight, including notes that investors are heavily searching the stock and that large-cap pharma names may benefit from an industry recovery. Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
• Negative Sentiment: Brazil approved the country’s first generic copy of Ozempic, which could increase pricing pressure and intensify competition in a fast-growing diabetes and weight-loss market. Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
• Negative Sentiment: A Zacks note also warned that EU label expansions may help semaglutide volumes, but pricing pressure and competition from Eli Lilly could limit any recovery in NVO shares. Can EU Label Expansions of NVO’s GLP-1 Drugs Spur Sales Growth?

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.